Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02950467 · ClinicalTrials.gov registry record · Phase 1
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
A Phase 1 study of Depression and Grief, sponsored by Joshua Woolley.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02950467 is a Phase 1 study of Depression and Grief that has completed, run by Joshua Woolley. The registered enrollment target is 30 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02950467, a Phase 1 study of Depression and Grief, has completed, sponsored by Joshua Woolley.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).
Conditions Studied
Interventions
- DRUG Psilocybin
- BEHAVIORAL Modified brief Supportive Expressive Group Therapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-01-05 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02950467
The ClinicalTrials.gov registry entry for NCT02950467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The listed sponsor is Joshua Woolley, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin is the first listed.
NCT02950467 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02950467 about?
NCT02950467 is a clinical study titled "Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors". The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).
What is the current status of trial NCT02950467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-01-05. Estimated completion is 2019-12-31.
What conditions does trial NCT02950467 study?
This clinical trial studies the following conditions: Depression, Grief, Distress.
What interventions are being tested in trial NCT02950467?
The interventions under investigation include: Psilocybin (DRUG), Modified brief Supportive Expressive Group Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02950467?
This trial is sponsored by Joshua Woolley, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02950467 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.